VO-OHPic is a reversible, noncompetitive, and selective inhibitor of PTEN with an IC50 of 46 nM. It effectively attenuates apoptosis, adverse cardiac remodeling, and the presence of pro-inflammatory M1 macrophages in models of doxorubicin-induced cardiomyopathy. Additionally, VO-OHPic inhibits autophagy [1] [2] [3].